Two studies published back to back in Nature have looked at the accumulation of mutations in blood-forming stem cells with age, gaining new insights into how the overall landscape of such cells changes across the lifespan.
Age is the biggest risk factor for just about every common disease in high-income countries, which suggests that slowing down cellular aging would have massive effects on individual and public health. Delaying the average onset of Alzheimer’s disease by five years, for example, would roughly halve its prevalence. But in practice, there are no approved anti-aging medications.
The mammalian target of rapamycin (mTOR) inhibitor rapamycin extended the lifespan of female but not male flies, through sex-specific effects on the enterocytes that line the gut.
Biotechs that tackle the effects of aging are beginning to make headlines: in January Altos Labs Inc. launched with a reported investment from Jeff Bezos. With Bezos getting involved with San Francisco-based Altos, the immediate reaction was that anti-aging biotechs would be there for the benefit of billionaires searching for eternal life.
Not so, according to London U.K.-based Genflow Biosciences plc, which hopes to show that fighting aging is really about improving health as people age.
By using roughly 400 data points, from molecular to physical fitness, researchers have gained new insights into how organs such as the heart vs. the skin, and systems such as the immune and metabolic systems, age at different rates within individuals.
An international collaborative study led by Australian scientists at the University of Queensland in Brisbane has demonstrated that dietary selenium supplementation mediates exercise-induced adult neurogenesis and reverses learning deficits induced by hippocampal injury and aging in mice.
Investigators at the University of Freiburg and Swiss startup Ultimate Medicine have identified a compound produced by the gut microbiome as contributing to age-related cognitive decline by modulating inhibitory synaptic transmission and neural network activity.
Movendo Technology srl and Maragal Medical PC have collaborated to provide free community screening for the risk of falls for Massachusetts Medicare patients using Movendo’s Hunova robotic technology. Hunova performs a progressive assessment on seated and standing patients to evaluate their flexibility, strength and balance. The system also provides personalized rehabilitative therapy recommendations.
Apollo Health Ventures raised $180 million for a new venture capital fund focused on biotechnology companies developing therapies for age-related diseases. It may also invest in healthtech and digital health opportunities, but the latter constitute a minority pursuit for an investment team that is building up capabilities and expertise in disease biology.
RSS
